Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2021)
Inhibikase Therapeutics (IKT) posted Current Deferred Revenue of $142,619 for Q2 2021, down 88.6% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2021) Analysis & Trends
At the end of FY2020, Inhibikase Therapeutics' Current Deferred Revenue came in at $2.33 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn |
| 10 | Inhibikase Therapeutics | 288.92 Mn | -296.56 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 142,619.00 |
| Mar 31, 2021 | 1.25 Mn |
| Dec 31, 2020 | 2.33 Mn |
API Access
Inhibikase Therapeutics Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();